Raymond James initiates coverage on Thor Industries (NYSE:THO) with a Underperform rating.
Wedbush Maintains Outperform on Ascendis Pharma, Lowers Price Target to $117
Wedbush analyst Liana Moussatos maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and lowers the price target from $128 to $117.